Clinical Trial Update: Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

Pfizer's Quillivant XR (methylphenidate extended-release) completed a Phase 3 trial for attention-deficit/hyperactivity disorder. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QUILLIVANT XR (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Pfizer | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-06-26